Corcept Therapeutics (CORT) Projected to Release Quarterly Earnings on Wednesday

Corcept Therapeutics (NASDAQ:CORT) is projected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Corcept Therapeutics to post earnings of $0.7940 per share and revenue of $323.90 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. The business had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. The firm’s quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 earnings per share. On average, analysts expect Corcept Therapeutics to post $1.83 EPS for the current fiscal year and $3.49 EPS for the next fiscal year.

Corcept Therapeutics Trading Up 0.5%

Shares of CORT stock opened at $87.59 on Wednesday. Corcept Therapeutics has a 1 year low of $28.66 and a 1 year high of $126.38. The stock has a 50 day simple moving average of $114.07 and a 200 day simple moving average of $73.91.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Truist Financial initiated coverage on Corcept Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $165.00 price target on shares of Corcept Therapeutics in a research note on Friday, September 18th. Finally, Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $138.17.

Insiders Place Their Bets

In related news, insider Sean Maduck sold 30,955 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $125.58, for a total transaction of $3,887,328.90. Following the sale, the insider directly owned 9,755 shares in the company, valued at $1,225,032.90. This trade represents a 76.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David L. Mahoney sold 103,606 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $118.25, for a total transaction of $12,251,409.50. Following the sale, the director directly owned 1,133,539 shares in the company, valued at $134,040,986.75. The trade was a 8.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 454,748 shares of company stock worth $52,786,210. Company insiders own 20.70% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.